Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Medicine Lab, |
RCV001375987 | SCV001572988 | pathogenic | CHARGE syndrome | 2020-05-14 | criteria provided, single submitter | clinical testing | |
Laboratory of Medical Genetics, |
RCV001375987 | SCV001976775 | pathogenic | CHARGE syndrome | 2021-08-10 | criteria provided, single submitter | clinical testing | PVS1, PM2, PP3 |
Genomic Medicine Lab, |
RCV001375987 | SCV002576368 | pathogenic | CHARGE syndrome | criteria provided, single submitter | clinical testing | ||
Prevention |
RCV003399192 | SCV004118777 | pathogenic | CHD7-related disorder | 2022-08-30 | criteria provided, single submitter | clinical testing | The CHD7 c.3422_3423delTG variant is predicted to result in a frameshift and premature protein termination (p.Val1141Glyfs*27). This variant has been previously observed and reported as de novo in a cohort of fetuses with unexplained nonimmune hydrops fetalis (Sparks et al. 2020. PubMed ID: 33027564). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in CHD7 are expected to be pathogenic. This variant is interpreted as pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV001375987 | SCV005093818 | pathogenic | CHARGE syndrome | 2024-08-05 | criteria provided, single submitter | clinical testing |